PHAXIAM Therapeutics S.A. (EPA:PHXM)

Market Cap	n/a
Revenue (ttm)	2.14M
Net Income (ttm)	-21.92M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0266 - 2.1450
Beta	1.74
RSI	26.35
Earnings Date	Sep 24, 2025

About PHAXIAM Therapeutics

PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 68
• Stock Exchange: Euronext Paris
• Ticker Symbol: PHXM

Financial Performance

In 2023, PHAXIAM Therapeutics's revenue was 1.33 million, a decrease of -80.05% compared to the previous year's 6.65 million. Losses were -23.49 million, 10201.8% more than in 2022.